APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Innovative Drug CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Innovative Drug CDMO Market Analysis and Forecast 2026-2032

Report ID 17416453024 January 2026193 pages

Choose your research edition.

Industry ResearchInnovative Drug CDMO Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Innovative Drug CDMO Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Innovative Drug CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Innovative Drug CDMO Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Innovative Drug CDMO Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Innovative Drug CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Innovative Drug CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Innovative Drug CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Innovative Drug CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Innovative Drug CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Innovative Drug CDMO include Skyepharma, Asymchem, Recipharm, Bend Bioscience, Pierre Fabre, Axplora, Quotient Sciences, Lonza and Ardena, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Innovative Drug CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Innovative Drug CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Innovative Drug CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Innovative Drug CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Innovative Drug CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Innovative Drug CDMO revenue, projected growth trends, production technology, application and end-user industry.

Innovative Drug CDMO Segment by Company

Skyepharma

Asymchem

Recipharm

Bend Bioscience

Pierre Fabre

Axplora

Quotient Sciences

Lonza

Ardena

Hovione

Resilience

AGC Biologics

Patheon Pharma Services

Samsung Biologics

Catalent

Innovative Drug CDMO Segment by Type

Small Molecule CDMO

Macromolecule CDMO

Cell Gene Therapy (CGT) CDMO

Innovative Drug CDMO Segment by Application

Oncology and Cancer Drugs

Autoimmune Disease Drugs

Rare Disease Drugs

Gene Therapy Drugs

Metabolic Disease Drugs

Others

Innovative Drug CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Innovative Drug CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Innovative Drug CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Innovative Drug CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Innovative Drug CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Innovative Drug CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Innovative Drug CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Innovative Drug CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Small Molecule CDMO Major Player Table 3. Macromolecule CDMO Major Player Table 4. Cell Gene Therapy (CGT) CDMO Major Player Table 5. Global Innovative Drug CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Oncology and Cancer Drugs Major Player Table 7. Autoimmune Disease Drugs Major Player Table 8. Rare Disease Drugs Major Player Table 9. Gene Therapy Drugs Major Player Table 10. Metabolic Disease Drugs Major Player Table 11. Others Major Player Table 12. Innovative Drug CDMO Industry Trends Table 13. Innovative Drug CDMO Industry Drivers Table 14. Innovative Drug CDMO Industry Opportunities and Challenges Table 15. Innovative Drug CDMO Industry Restraints Table 16. Global Innovative Drug CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Innovative Drug CDMO Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Innovative Drug CDMO Market Share by Region (2021-2026) Table 19. Global Innovative Drug CDMO Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Innovative Drug CDMO Market Share by Region (2027-2032) Table 21. Global Innovative Drug CDMO Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Innovative Drug CDMO Revenue Market Share by Players (2021-2026) Table 23. Global Innovative Drug CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Innovative Drug CDMO Key Players Headquarters & Area Served Table 25. Global Innovative Drug CDMO Players, Product Type & Application Table 26. Global Innovative Drug CDMO Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Innovative Drug CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Innovative Drug CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Innovative Drug CDMO Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Innovative Drug CDMO Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Innovative Drug CDMO Revenue Market Share by Type (2021-2026) Table 33. Global Innovative Drug CDMO Revenue Market Share by Type (2027-2032) Table 34. Global Innovative Drug CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Innovative Drug CDMO Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Innovative Drug CDMO Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Innovative Drug CDMO Revenue Market Share by Application (2021-2026) Table 38. Global Innovative Drug CDMO Revenue Market Share by Application (2027-2032) Table 39. Skyepharma Company Information Table 40. Skyepharma Business Overview Table 41. Skyepharma Innovative Drug CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Skyepharma Innovative Drug CDMO Product Portfolio Table 43. Skyepharma Recent Development Table 44. Asymchem Company Information Table 45. Asymchem Business Overview Table 46. Asymchem Innovative Drug CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Asymchem Innovative Drug CDMO Product Portfolio Table 48. Asymchem Recent Development Table 49. Recipharm Company Information Table 50. Recipharm Business Overview Table 51. Recipharm Innovative Drug CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Recipharm Innovative Drug CDMO Product Portfolio Table 53. Recipharm Recent Development Table 54. Bend Bioscience Company Information Table 55. Bend Bioscience Business Overview Table 56. Bend Bioscience Innovative Drug CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Bend Bioscience Innovative Drug CDMO Product Portfolio Table 58. Bend Bioscience Recent Development Table 59. Pierre Fabre Company Information Table 60. Pierre Fabre Business Overview Table 61. Pierre Fabre Innovative Drug CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Pierre Fabre Innovative Drug CDMO Product Portfolio Table 63. Pierre Fabre Recent Development Table 64. Axplora Company Information Table 65. Axplora Business Overview Table 66. Axplora Innovative Drug CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Axplora Innovative Drug CDMO Product Portfolio Table 68. Axplora Recent Development Table 69. Quotient Sciences Company Information Table 70. Quotient Sciences Business Overview Table 71. Quotient Sciences Innovative Drug CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Quotient Sciences Innovative Drug CDMO Product Portfolio Table 73. Quotient Sciences Recent Development Table 74. Lonza Company Information Table 75. Lonza Business Overview Table 76. Lonza Innovative Drug CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Lonza Innovative Drug CDMO Product Portfolio Table 78. Lonza Recent Development Table 79. Ardena Company Information Table 80. Ardena Business Overview Table 81. Ardena Innovative Drug CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Ardena Innovative Drug CDMO Product Portfolio Table 83. Ardena Recent Development Table 84. Hovione Company Information Table 85. Hovione Business Overview Table 86. Hovione Innovative Drug CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Hovione Innovative Drug CDMO Product Portfolio Table 88. Hovione Recent Development Table 89. Resilience Company Information Table 90. Resilience Business Overview Table 91. Resilience Innovative Drug CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Resilience Innovative Drug CDMO Product Portfolio Table 93. Resilience Recent Development Table 94. AGC Biologics Company Information Table 95. AGC Biologics Business Overview Table 96. AGC Biologics Innovative Drug CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. AGC Biologics Innovative Drug CDMO Product Portfolio Table 98. AGC Biologics Recent Development Table 99. Patheon Pharma Services Company Information Table 100. Patheon Pharma Services Business Overview Table 101. Patheon Pharma Services Innovative Drug CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Patheon Pharma Services Innovative Drug CDMO Product Portfolio Table 103. Patheon Pharma Services Recent Development Table 104. Samsung Biologics Company Information Table 105. Samsung Biologics Business Overview Table 106. Samsung Biologics Innovative Drug CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Samsung Biologics Innovative Drug CDMO Product Portfolio Table 108. Samsung Biologics Recent Development Table 109. Catalent Company Information Table 110. Catalent Business Overview Table 111. Catalent Innovative Drug CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Catalent Innovative Drug CDMO Product Portfolio Table 113. Catalent Recent Development Table 114. North America Innovative Drug CDMO Revenue by Type (2021-2026) & (US$ Million) Table 115. North America Innovative Drug CDMO Revenue by Type (2027-2032) & (US$ Million) Table 116. North America Innovative Drug CDMO Revenue by Application (2021-2026) & (US$ Million) Table 117. North America Innovative Drug CDMO Revenue by Application (2027-2032) & (US$ Million) Table 118. North America Innovative Drug CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. North America Innovative Drug CDMO Revenue by Country (2021-2026) & (US$ Million) Table 120. North America Innovative Drug CDMO Revenue by Country (US$ Million) & (2027-2032) Table 121. Europe Innovative Drug CDMO Revenue by Type (2021-2026) & (US$ Million) Table 122. Europe Innovative Drug CDMO Revenue by Type (2027-2032) & (US$ Million) Table 123. Europe Innovative Drug CDMO Revenue by Application (2021-2026) & (US$ Million) Table 124. Europe Innovative Drug CDMO Revenue by Application (2027-2032) & (US$ Million) Table 125. Europe Innovative Drug CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Europe Innovative Drug CDMO Revenue by Country (2021-2026) & (US$ Million) Table 127. Europe Innovative Drug CDMO Revenue by Country (US$ Million) & (2027-2032) Table 128. China Innovative Drug CDMO Revenue by Type (2021-2026) & (US$ Million) Table 129. China Innovative Drug CDMO Revenue by Type (2027-2032) & (US$ Million) Table 130. China Innovative Drug CDMO Revenue by Application (2021-2026) & (US$ Million) Table 131. China Innovative Drug CDMO Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Innovative Drug CDMO Revenue by Type (2021-2026) & (US$ Million) Table 133. Asia Innovative Drug CDMO Revenue by Type (2027-2032) & (US$ Million) Table 134. Asia Innovative Drug CDMO Revenue by Application (2021-2026) & (US$ Million) Table 135. Asia Innovative Drug CDMO Revenue by Application (2027-2032) & (US$ Million) Table 136. Asia Innovative Drug CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Asia Innovative Drug CDMO Revenue by Region (US$ Million) & (2021-2026) Table 138. Asia Innovative Drug CDMO Revenue by Region (US$ Million) & (2027-2032) Table 139. SAMEA Innovative Drug CDMO Revenue by Type (2021-2026) & (US$ Million) Table 140. SAMEA Innovative Drug CDMO Revenue by Type (2027-2032) & (US$ Million) Table 141. SAMEA Innovative Drug CDMO Revenue by Application (2021-2026) & (US$ Million) Table 142. SAMEA Innovative Drug CDMO Revenue by Application (2027-2032) & (US$ Million) Table 143. SAMEA Innovative Drug CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. SAMEA Innovative Drug CDMO Revenue by Country (2021-2026) & (US$ Million) Table 145. SAMEA Innovative Drug CDMO Revenue by Country (US$ Million) & (2027-2032) Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Innovative Drug CDMO Image Figure 2. Global Innovative Drug CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Innovative Drug CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Small Molecule CDMO Image Figure 5. Macromolecule CDMO Image Figure 6. Cell Gene Therapy (CGT) CDMO Image Figure 7. Global Innovative Drug CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Innovative Drug CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 9. Oncology and Cancer Drugs Image Figure 10. Autoimmune Disease Drugs Image Figure 11. Rare Disease Drugs Image Figure 12. Gene Therapy Drugs Image Figure 13. Metabolic Disease Drugs Image Figure 14. Others Image Figure 15. Global Innovative Drug CDMO Market Size (US$ Million) & (2021-2032) Figure 16. Global Innovative Drug CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Innovative Drug CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Innovative Drug CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Innovative Drug CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Innovative Drug CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Innovative Drug CDMO Revenue Market Share by Type (2021-2032) Figure 23. Global Innovative Drug CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Innovative Drug CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Innovative Drug CDMO Revenue Market Share by Application (2021-2032) Figure 26. North America Innovative Drug CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Innovative Drug CDMO Revenue Share by Type (2021-2032) Figure 28. North America Innovative Drug CDMO Revenue Share by Application (2021-2032) Figure 29. North America Innovative Drug CDMO Revenue Share by Country (2021-2032) Figure 30. United States Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Innovative Drug CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Innovative Drug CDMO Revenue Share by Type (2021-2032) Figure 35. Europe Innovative Drug CDMO Revenue Share by Application (2021-2032) Figure 36. Europe Innovative Drug CDMO Revenue Share by Country (2021-2032) Figure 37. Germany Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Innovative Drug CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Innovative Drug CDMO Revenue Share by Type (2021-2032) Figure 47. China Innovative Drug CDMO Revenue Share by Application (2021-2032) Figure 48. Asia Innovative Drug CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Innovative Drug CDMO Revenue Share by Type (2021-2032) Figure 50. Asia Innovative Drug CDMO Revenue Share by Application (2021-2032) Figure 51. Asia Innovative Drug CDMO Revenue Share by Region (2021-2032) Figure 52. Japan Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Innovative Drug CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Innovative Drug CDMO Revenue Share by Type (2021-2032) Figure 60. SAMEA Innovative Drug CDMO Revenue Share by Application (2021-2032) Figure 61. SAMEA Innovative Drug CDMO Revenue Share by Country (2021-2032) Figure 62. Brazil Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Innovative Drug CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecule CDMO
  • Macromolecule CDMO
  • Cell Gene Therapy (CGT) CDMO
Applications
  • Oncology and Cancer Drugs
  • Autoimmune Disease Drugs
  • Rare Disease Drugs
  • Gene Therapy Drugs
  • Metabolic Disease Drugs
  • Others
Companies covered
  • Skyepharma
  • Asymchem
  • Recipharm
  • Bend Bioscience
  • Pierre Fabre
  • Axplora
  • Quotient Sciences
  • Lonza
  • Ardena
  • Hovione
  • Resilience
  • AGC Biologics
  • Patheon Pharma Services
  • Samsung Biologics
  • Catalent

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Innovative Drug CDMO Market by Type
  3. 1.2.1 Global Innovative Drug CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Small Molecule CDMO
  5. 1.2.3 Macromolecule CDMO
  6. 1.2.4 Cell Gene Therapy (CGT) CDMO
  7. 1.3 Innovative Drug CDMO Market by Application
  8. 1.3.1 Global Innovative Drug CDMO Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Oncology and Cancer Drugs
  10. 1.3.3 Autoimmune Disease Drugs
  11. 1.3.4 Rare Disease Drugs
  12. 1.3.5 Gene Therapy Drugs
  13. 1.3.6 Metabolic Disease Drugs
  14. 1.3.7 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Innovative Drug CDMO Market Dynamics
  1. 2.1 Innovative Drug CDMO Industry Trends
  2. 2.2 Innovative Drug CDMO Industry Drivers
  3. 2.3 Innovative Drug CDMO Industry Opportunities and Challenges
  4. 2.4 Innovative Drug CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Innovative Drug CDMO Market Perspective (2021-2032)
  2. 3.2 Global Innovative Drug CDMO Growth Trends by Region
  3. 3.2.1 Global Innovative Drug CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Innovative Drug CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Innovative Drug CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Innovative Drug CDMO Revenue by Players
  2. 4.1.1 Global Innovative Drug CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Innovative Drug CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Innovative Drug CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Innovative Drug CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Innovative Drug CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Innovative Drug CDMO Players, Product Type & Application
  8. 4.5 Global Innovative Drug CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Innovative Drug CDMO Market CR5 and HHI
  11. 4.6.3 2025 Innovative Drug CDMO Tier 1, Tier 2, and Tier 3
5 Innovative Drug CDMO Market Size by Type
  1. 5.1 Global Innovative Drug CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Innovative Drug CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Innovative Drug CDMO Revenue Market Share by Type (2021-2032)
6 Innovative Drug CDMO Market Size by Application
  1. 6.1 Global Innovative Drug CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Innovative Drug CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Innovative Drug CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Skyepharma
  2. 7.1.1 Skyepharma Company Information
  3. 7.1.2 Skyepharma Business Overview
  4. 7.1.3 Skyepharma Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Skyepharma Innovative Drug CDMO Product Portfolio
  6. 7.1.5 Skyepharma Recent Developments
  7. 7.2 Asymchem
  8. 7.2.1 Asymchem Company Information
  9. 7.2.2 Asymchem Business Overview
  10. 7.2.3 Asymchem Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Asymchem Innovative Drug CDMO Product Portfolio
  12. 7.2.5 Asymchem Recent Developments
  13. 7.3 Recipharm
  14. 7.3.1 Recipharm Company Information
  15. 7.3.2 Recipharm Business Overview
  16. 7.3.3 Recipharm Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Recipharm Innovative Drug CDMO Product Portfolio
  18. 7.3.5 Recipharm Recent Developments
  19. 7.4 Bend Bioscience
  20. 7.4.1 Bend Bioscience Company Information
  21. 7.4.2 Bend Bioscience Business Overview
  22. 7.4.3 Bend Bioscience Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bend Bioscience Innovative Drug CDMO Product Portfolio
  24. 7.4.5 Bend Bioscience Recent Developments
  25. 7.5 Pierre Fabre
  26. 7.5.1 Pierre Fabre Company Information
  27. 7.5.2 Pierre Fabre Business Overview
  28. 7.5.3 Pierre Fabre Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pierre Fabre Innovative Drug CDMO Product Portfolio
  30. 7.5.5 Pierre Fabre Recent Developments
  31. 7.6 Axplora
  32. 7.6.1 Axplora Company Information
  33. 7.6.2 Axplora Business Overview
  34. 7.6.3 Axplora Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Axplora Innovative Drug CDMO Product Portfolio
  36. 7.6.5 Axplora Recent Developments
  37. 7.7 Quotient Sciences
  38. 7.7.1 Quotient Sciences Company Information
  39. 7.7.2 Quotient Sciences Business Overview
  40. 7.7.3 Quotient Sciences Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Quotient Sciences Innovative Drug CDMO Product Portfolio
  42. 7.7.5 Quotient Sciences Recent Developments
  43. 7.8 Lonza
  44. 7.8.1 Lonza Company Information
  45. 7.8.2 Lonza Business Overview
  46. 7.8.3 Lonza Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Lonza Innovative Drug CDMO Product Portfolio
  48. 7.8.5 Lonza Recent Developments
  49. 7.9 Ardena
  50. 7.9.1 Ardena Company Information
  51. 7.9.2 Ardena Business Overview
  52. 7.9.3 Ardena Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Ardena Innovative Drug CDMO Product Portfolio
  54. 7.9.5 Ardena Recent Developments
  55. 7.10 Hovione
  56. 7.10.1 Hovione Company Information
  57. 7.10.2 Hovione Business Overview
  58. 7.10.3 Hovione Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Hovione Innovative Drug CDMO Product Portfolio
  60. 7.10.5 Hovione Recent Developments
  61. 7.11 Resilience
  62. 7.11.1 Resilience Company Information
  63. 7.11.2 Resilience Business Overview
  64. 7.11.3 Resilience Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Resilience Innovative Drug CDMO Product Portfolio
  66. 7.11.5 Resilience Recent Developments
  67. 7.12 AGC Biologics
  68. 7.12.1 AGC Biologics Company Information
  69. 7.12.2 AGC Biologics Business Overview
  70. 7.12.3 AGC Biologics Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AGC Biologics Innovative Drug CDMO Product Portfolio
  72. 7.12.5 AGC Biologics Recent Developments
  73. 7.13 Patheon Pharma Services
  74. 7.13.1 Patheon Pharma Services Company Information
  75. 7.13.2 Patheon Pharma Services Business Overview
  76. 7.13.3 Patheon Pharma Services Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Patheon Pharma Services Innovative Drug CDMO Product Portfolio
  78. 7.13.5 Patheon Pharma Services Recent Developments
  79. 7.14 Samsung Biologics
  80. 7.14.1 Samsung Biologics Company Information
  81. 7.14.2 Samsung Biologics Business Overview
  82. 7.14.3 Samsung Biologics Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Samsung Biologics Innovative Drug CDMO Product Portfolio
  84. 7.14.5 Samsung Biologics Recent Developments
  85. 7.15 Catalent
  86. 7.15.1 Catalent Company Information
  87. 7.15.2 Catalent Business Overview
  88. 7.15.3 Catalent Innovative Drug CDMO Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Catalent Innovative Drug CDMO Product Portfolio
  90. 7.15.5 Catalent Recent Developments
8 North America
  1. 8.1 North America Innovative Drug CDMO Revenue (2021-2032)
  2. 8.2 North America Innovative Drug CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Innovative Drug CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Innovative Drug CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Innovative Drug CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Innovative Drug CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Innovative Drug CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Innovative Drug CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Innovative Drug CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Innovative Drug CDMO Revenue by Country
  11. 8.6.1 North America Innovative Drug CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Innovative Drug CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Innovative Drug CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Innovative Drug CDMO Revenue (2021-2032)
  2. 9.2 Europe Innovative Drug CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Innovative Drug CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Innovative Drug CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Innovative Drug CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Innovative Drug CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Innovative Drug CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Innovative Drug CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Innovative Drug CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Innovative Drug CDMO Revenue by Country
  11. 9.6.1 Europe Innovative Drug CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Innovative Drug CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Innovative Drug CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Innovative Drug CDMO Revenue (2021-2032)
  2. 10.2 China Innovative Drug CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Innovative Drug CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Innovative Drug CDMO Revenue by Type (2027-2032)
  5. 10.3 China Innovative Drug CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Innovative Drug CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Innovative Drug CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Innovative Drug CDMO Revenue by Application (2027-2032)
  9. 10.5 China Innovative Drug CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Innovative Drug CDMO Revenue (2021-2032)
  2. 11.2 Asia Innovative Drug CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Innovative Drug CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Innovative Drug CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Innovative Drug CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Innovative Drug CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Innovative Drug CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Innovative Drug CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Innovative Drug CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Innovative Drug CDMO Revenue by Country
  11. 11.6.1 Asia Innovative Drug CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Innovative Drug CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Innovative Drug CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Innovative Drug CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Innovative Drug CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Innovative Drug CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Innovative Drug CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Innovative Drug CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Innovative Drug CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Innovative Drug CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Innovative Drug CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Innovative Drug CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Innovative Drug CDMO Revenue by Country
  11. 12.6.1 SAMEA Innovative Drug CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Innovative Drug CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Innovative Drug CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst